Pharmacoeconomic considerations in the management of acute tumor lysis syndrome

被引：4

作者：

Farber, MS ^{[1
]}

机构：

[1] Detroit Med Ctr, Dept Pharm Serv, Detroit, MI 48201 USA

来源：

SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 02期

关键词：

D O I：

10.1053/sonc.2001.21185

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：19 / 22

页数：4

共 14 条

[1]

[Anonymous], 1999, AM J HEALTH-SYST PH, V56, P729

[2]

COX F, 1993, ONCOLOGY, V50, P186

[3]

DEITCH EA, 1990, SURGERY, V107, P411

[4] Filgrastim - A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia [J].

Frampton, JE ;

Faulds, D .

PHARMACOECONOMICS, 1996, 9 (01) :76-96

[5] Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia [J].

Hartmann, LC ;

Tschettier, LK ;

Habermann, TM ;

Ebbert, LP ;

Johnson, PS ;

Mailliard, JA ;

Levitt, R ;

Suman, VJ ;

Witzig, TE ;

Wieand, HS ;

Miller, LL ;

Moertel, CG .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (25) :1776-1780

[6] PHARMACIST-MANAGED INTRAVENOUS TO ORAL STEP-DOWN PROGRAM [J].

HUNTER, KA ;

DORMAIER, GK .

CLINICAL THERAPEUTICS, 1995, 17 (03) :534-540

[7]

Johnson N E, 1993, Pharmacoeconomics, V3, P471, DOI 10.2165/00019053-199303060-00007

[8] Gastrointestinal permeability and absorptive capacity in sepsis [J].

Johnston, JD ;

Harvey, CJ ;

Menzies, IS ;

Treacher, DF .

CRITICAL CARE MEDICINE, 1996, 24 (07) :1144-1149

[9]

Kshirsagar AV, 2000, J AM SOC NEPHROL, V11, P1526, DOI 10.1681/ASN.V1181526

[10] COMPLIANCE WITH ORAL-DRUG THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCY [J].

LEVINE, AM ;

RICHARDSON, JL ;

MARKS, G ;

CHAN, K ;

GRAHAM, J ;

SELSER, JN ;

KISHBAUGH, C ;

SHELTON, DR ;

JOHNSON, CA .

JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) :1469-1476

← 1 2 →